NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 68.22.
| Share Price | ₹12,798.8 | Jan 27,2026 |
| Market Cap | ₹16,382.5 Cr | |
| Earnings-TTM | ₹240.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 68.22x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹16,382.5 Cr] as on Jan 27,2026
(/) Earnings [ ₹240.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 68.22x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 68.22 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NEULAND LABORATORIES | 240.15 | 68.22 | 16,382.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 37.40 | 393,323.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 64.72 | 160,825.0 |
| CIPLA LTD | 4,544.70 | 23.33 | 106,048.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 63.25 | 135,349.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.79 | 103,494.0 |
| MANKIND PHARMA LTD | 1,767.06 | 48.92 | 86,451.7 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.08 | 89,902.0 |
| LUPIN LTD | 4,347.53 | 22.57 | 98,102.1 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.04 | 65,639.3 |
| ABBOTT INDIA LTD | 1,508.95 | 38.99 | 58,827.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.08x |
| Max industry PE | 68.22x |
| Median industry PE | 37.40x |
| Average industry PE | 38.48x |
You may also like the below Video Courses